Biome Australia – Company presentation April 2024
Biome Business Opportunity Novel range of Live Biotherapeutics with co-prescribing medication opportunity Landmark IP Deal executed on novel probiotic strains… Read more
Biome Business Opportunity Novel range of Live Biotherapeutics with co-prescribing medication opportunity Landmark IP Deal executed on novel probiotic strains… Read more
● Biome records first positive quarterly EBITDA (unaudited) in Q3 FY24 ● Biome records first positive quarter of underlying operating… Read more
● Biome Australia achieves cash-flow positive milestone in Q3 FY24 ● Biome records $3.2m in sales in Q3, representing 74%… Read more
Biome Australia Limited Appendix 4D Half-year report
Biome Releases First Half FY2024 Results ● Biome reports record half year and quarterly sales revenue (H1FY24 $6.02m; Q2FY24 $3.3m)… Read more
Highlights ● Biome reports record $3.3m sales revenue and $3.07m cash receipts in Q2 FY24 ● Biome records first… Read more
Biome to launch into UK and Ireland health retail markets ● Launch of Biome’s Activated Probiotics into key European health… Read more
On Monday this week, Biome Australia Limited (ASX: BIO) announced an upgrade to their FY2024 revenue forecast from $11.5m to… Read more
Happy New Year from Canary Capital. Biome Australia has this morning announced record sales revenue for both the December quarter… Read more